{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "22421155",
  "DateCompleted": {
    "Year": "2013",
    "Month": "01",
    "Day": "04"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2012",
        "Month": "04",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.4161/cc.19890"
    ],
    "Journal": {
      "ISSN": "1551-4005",
      "JournalIssue": {
        "Volume": "11",
        "Issue": "7",
        "PubDate": {
          "Year": "2012",
          "Month": "Apr",
          "Day": "01"
        }
      },
      "Title": "Cell cycle (Georgetown, Tex.)",
      "ISOAbbreviation": "Cell Cycle"
    },
    "ArticleTitle": "Antiangiogenic agents: fueling cancer's hypoxic roots.",
    "Pagination": {
      "StartPage": "1265",
      "EndPage": "1266",
      "MedlinePgn": "1265-6"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Conley",
        "ForeName": "Sarah J",
        "Initials": "SJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wicha",
        "ForeName": "Max S",
        "Initials": "MS"
      }
    ],
    "PublicationTypeList": [
      "Editorial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cell Cycle",
    "NlmUniqueID": "101137841",
    "ISSNLinking": "1551-4005"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiogenesis Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Monoclonal, Humanized"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Indoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrroles"
    },
    {
      "RegistryNumber": "2S9ZZM9Q9V",
      "NameOfSubstance": "Bevacizumab"
    },
    {
      "RegistryNumber": "V99T50803M",
      "NameOfSubstance": "Sunitinib"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Angiogenesis Inhibitors"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Antibodies, Monoclonal, Humanized"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Bevacizumab"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cell Hypoxia"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Indoles"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathology"
      ],
      "DescriptorName": "Neoplastic Stem Cells"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Neovascularization, Pathologic"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Pyrroles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sunitinib"
    }
  ]
}